We hypothesize that a novel capsid incorporation approach will allow comprehensive in vivo monitoring of a cancer retargeted vector, and permit the assessment of our novel vector engineering strategy to enable targeted therapy of disseminated neoplastic disease. By investigating adenovirus (Ad) vector design, we anticipate the new information gained from this initiative will demonstrate the utility of our highly novel imaging approach, and validate the specificity of retargeted tumor transduction. The goal of this application is to develop a multi-functional Ad vector that combines both imaging and targeted therapy. To fulfill this goal, we will combine three unique technologies to advance therapeutic targeting of disseminated neoplastic disease: cancer-specific retargeting, liver-detargeting, and non-invasive imaging. We have developed Ad vectors capable of cell-specific targeting, by incorporating targeting single chain antibodies (scFv) into the viral capsid in combination with hexon modification for liver detargeting and evasion of pre-existing immunity. Our innovative Ad targeting approach provides a novel way to circumvent the problem of structural and biosynthetic incompatibility between Ad and complex targeting ligands such as scFv, and could facilitate Ad targeting to a wide variety of clinically important cell populations using novel targeting ligands including recombinant antibodies and growth factors The goal of this application is to develop a multi-functional Ad vector that combines both imaging and targeted therapy. To fulfill this goal, we will combine three unique technologies to advance therapeutic targeting of disseminated neoplastic disease: cancer-specific retargeting, liver-detargeting, and non-invasive imaging. We have developed Ad vectors capable of cell-specific targeting, by incorporating targeting single chain antibodies (scFv) into the viral capsid in combination with hexon modification for liver detargeting and evasion of pre-existing immunity. Our innovative Ad targeting approach provides a novel way to circumvent the problem of structural and biosynthetic incompatibility between Ad and complex targeting ligands such as scFv, and could facilitate Ad targeting to a wide variety of clinically important cell populations Our innovative use of a structural fusion protein incorporating metallothionein into adenovirus pIX gene provides the non-invasive imaging advantages of detecting physical biodistribution and spread of Ad vectors after administration that is not possible employing a reporter gene. Further, the ability to noninvasively observe Ad function on a whole-body level allows the possibility of detecting virus dissemination outside the tumor site(s) for monitoring clinical safety. By combining these modifications in Ad vector design, we anticipate the new information gained from this initiative will demonstrate the utility of our highly novel imaging approach, and validate the specificity of targeted tumor transduction. This work addresses the significant unmet need of new therapies for advanced stage metastatic cancer. The novel design of the proposed imaging approach is distinct from previously described vector imaging modalities, which have been based exclusively on monitoring the expression of reporter genes. In addition, our combined technologies have broad impact on the diverse field of gene therapy, in which the ability to achieve both cell- specific transduction and monitoring is universally required. To accomplish these goals, we have assembled an outstanding team of investigators with expertise in Ad vector design and construction, adenovirus retargeting approaches, preclinical models using Ad vectors, non-invasive PET and SPECT imaging, medical physics, colon cancer oncology and clinical trials, clinical pathology, biostatistics, and preclinical toxicology.

Public Health Relevance

The goal of this application is to develop a multi-functional adenovirus vector that combines both imaging and targeted therapy. We will provide a combination of modifications that are optimal for cell-specific adenovirus targeting in metastatic colon cancer gene therapy and for monitoring adenovirus biodistribution by non- invasive SPECT and PET imaging.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA154697-01A1
Application #
8183787
Study Section
Clinical Molecular Imaging and Probe Development (CMIP)
Program Officer
Farahani, Keyvan
Project Start
2011-09-26
Project End
2016-07-31
Budget Start
2011-09-26
Budget End
2012-07-31
Support Year
1
Fiscal Year
2011
Total Cost
$517,924
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Stephens, Calvin J; Kashentseva, Elena; Everett, William et al. (2018) Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9. Gene Ther 25:139-156
Lu, Zhi Hong; Kaliberov, Sergey; Sohn, Rebecca E et al. (2017) A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector. Oncotarget 8:12272-12289
Bhatia, Shilpa; O'Bryan, Samia M; Rivera, Angel A et al. (2016) CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter. Oncolytic Virother 5:99-113
Kaliberov, S A; Kaliberova, L N; Yan, H et al. (2016) Retargeted adenoviruses for radiation-guided gene delivery. Cancer Gene Ther 23:303-14
Sakr, Hany I; Coleman, David T; Cardelli, James A et al. (2015) Characterization of an Oncolytic Adenovirus Vector Constructed to Target the cMet Receptor. Oncolytic Virother 4:119-132
van Erp, Elisabeth A; Kaliberova, Lyudmila N; Kaliberov, Sergey A et al. (2015) Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein. Mol Ther Oncolytics 2:15001
Liu, Lei; Rogers, Buck E; Aladyshkina, Natalia et al. (2014) Construction and radiolabeling of adenovirus variants that incorporate human metallothionein into protein IX for analysis of biodistribution. Mol Imaging 13:
Lu, Zhi Hong; Kaliberov, Sergey; Zhang, Jingzhu et al. (2014) The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting. Lab Invest 94:881-92
Kaliberov, Sergey A; Kaliberova, Lyudmila N; Buggio, Maurizio et al. (2014) Adenoviral targeting using genetically incorporated camelid single variable domains. Lab Invest 94:893-905
Uchino, Junji; Curiel, David T; Ugai, Hideyo (2014) Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes. PLoS One 9:e87342

Showing the most recent 10 out of 15 publications